ProMetic Life Sciences Inc. (TSE:PLI) has received an average recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is C$3.60.

A number of analysts have recently issued reports on PLI shares. Canaccord Genuity dropped their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Royal Bank Of Canada dropped their target price on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research report on Wednesday, August 16th. National Bank Financial lifted their target price on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. Scotiabank dropped their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research report on Friday, July 7th. Finally, TD Securities dropped their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 16th.

COPYRIGHT VIOLATION NOTICE: “ProMetic Life Sciences Inc. (PLI) Receives Consensus Recommendation of “Buy” from Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/24/prometic-life-sciences-inc-pli-receives-consensus-recommendation-of-buy-from-brokerages.html.

ProMetic Life Sciences (TSE PLI) remained flat at $1.56 on Friday. The company’s stock had a trading volume of 722,272 shares. The stock’s market cap is $1.10 billion. ProMetic Life Sciences has a 1-year low of $1.12 and a 1-year high of $3.24. The stock’s 50 day moving average price is $1.42 and its 200-day moving average price is $1.85.

In related news, Director Louise Ménard sold 82,202 shares of ProMetic Life Sciences stock in a transaction dated Monday, July 10th. The stock was sold at an average price of C$1.60, for a total value of C$131,523.20. Also, Director Pierre Laurin sold 82,738 shares of ProMetic Life Sciences stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of C$1.44, for a total value of C$119,142.72. Over the last quarter, insiders purchased 98,700 shares of company stock valued at $124,003 and sold 470,599 shares valued at $639,100.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.